Advertisement

Antihypertonika

  • Manfred Anlauf
  • Franz Weber

Zusammenfassung

In diesem Kapitel zu speziellen Antihypertonika werden neben den Empfehlungen zur antihypertensiven Therapie Alpharezeptorenblocker und zentral wirkende Antisympathotonika sowie Kombinationspräparate von Betarezeptorenblockern und Calciumantagonisten dargestellt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Anlauf M (1994): Hypertonie im Alter. MMV Medizin Verlag, MünchenGoogle Scholar
  2. Anlauf M, Hense HW (2003): Echte und vermeintliche Sparpotenziale in der Hochdrucktherapie – Neues aus dem Zauberhut. Dtsch Med Wschr 128: 1557–1559PubMedGoogle Scholar
  3. Anlauf M, Weber F (2005): Bedeutung der Therapie mit Antihypertensiva für die kardiovaskuläre Prävention. In: Bundesärztekammer Berlin (Hrgs): Fortschritt und Fortbildung in der Medizin, Band 29, Deutscher Ärzte-Verlag, KölnGoogle Scholar
  4. Anlauf M, Weber F (2012): Neues Verfahren, aber für wen? Deutsches Ärzteblatt 109: 31–3Google Scholar
  5. Anlauf M (2013):Individualisierte Entscheidungen bei der Behandlung der Hypertonie. Arzneiverordnung in der Praxis 40: 2–4Google Scholar
  6. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forciea MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ, Harrington RA; ACCF Task Force; ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (2011): Circulation 123: 2434–2506PubMedCrossRefGoogle Scholar
  7. Arzneimittelkommission der Deutschen Ärzteschaft (2004): Empfehlungen zur Therapie der arteriellen Hypertonie. 2. Auflage, Arzneiverordnung in der Praxis, Band 31, Sonderheft 2 (Therapieempfehlungen), Internet: www.akdae.de/35/74_Hypertonie_2004_2Auflage.pdfGoogle Scholar
  8. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, Ohman EM, Cannon CP, Smith SC, Zeymer U, Hoffman EB, Messerli FH, Bhatt DL; REACH Registry Investigators (2012): ß-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 308: 1340–1349PubMedCrossRefGoogle Scholar
  9. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators (2014): A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370: 1393–1401PubMedCrossRefGoogle Scholar
  10. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group (2008): Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358: 1887–1898Google Scholar
  11. Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J, McCormack T, Forette F, Gil-Extremera B, Dumitrascu D, Staessen JA, Thijs L, Fletcher A, Bulpitt C; HYVET Study Group (2011): Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 2011 Jan 4; 344: d7541CrossRefGoogle Scholar
  12. Blood Pressure Lowering Treatment Trialists' Collaboration (2000): Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356: 1955–1964Google Scholar
  13. Blood Pressure Lowering Treatment Trialists` Collaboration (2007): Blood Pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J. Hypertension 25: 951–958Google Scholar
  14. Boger-Megiddo I, Heckbert SR, Weiss NS, McKnight B, Furberg CD, Wiggins KL, Delaney JA, Siscovick DS, Larson EB, Lemaitre RN, Smith NL, Rice KM, Glazer NL, Psaty BM (2010): Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. BMJ 340:c103PubMedCentralPubMedCrossRefGoogle Scholar
  15. Brown MJ (2011): Personalised medicine for hypertension. BMJ 343:d4697PubMedCrossRefGoogle Scholar
  16. Campbell CY, Blumenthal RS (2012): Pharmacogenetics of antihypertensive response. Hypertension 59: 1094–1096PubMedCrossRefGoogle Scholar
  17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee (2003): The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289: 2560–2571Google Scholar
  18. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ; MOXCON Investigators (2003): Adverse mortality effect of central sympathetic inhibition with sustained- release moxonidine in patients with heart failure. Eur J Heart Fail 5: 659–667PubMedCrossRefGoogle Scholar
  19. Dahlöf B, Sever PS, Neil R, Poulter NP, Wedel H (2005): Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366: 895–906PubMedCrossRefGoogle Scholar
  20. Dasgupta K, Quinn RR, Zarnke KB et al (2014): The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 30: 485–501PubMedCrossRefGoogle Scholar
  21. Davis BR, Piller LB, Cutler JA, Curt Furberg C, Dunn K, Franklin S, Goff D, Leenen F, Mohiuddin S, Papademetriou V, Proschan M, Ellsworth A, Golden J, Colon P, Crow R; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group (2006): Role of diuretics in the prevention of heart failure. The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial. Circulation 113: 2201–2210PubMedGoogle Scholar
  22. Deutsche Liga zur Bekämpfung des hohen Blutdrucks (2011): Neue Entwicklungen in der Hochdrucktherapie. http://www.hochdruckliga.de/tl_files/content/dhl/downloads/DHL-Leitlinien-2011.pdf (12.06.2012)
  23. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS (2012): Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 59: 1124–1131PubMedCentralPubMedCrossRefGoogle Scholar
  24. Elliott WJ, Meyer PM (2007): Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201–207PubMedGoogle Scholar
  25. Falaschetti E, Mindell J, Knott C, Poulter N (2014): Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet 383: 1912–1919PubMedCrossRefGoogle Scholar
  26. Galiè, N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group (2005): Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353: 2148–2157PubMedCrossRefGoogle Scholar
  27. Galiè N, Rubin Lj, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G (2008): Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371: 2093–2100PubMedCrossRefGoogle Scholar
  28. Giles TD, Weber MA, Basile J, Gradman AH, Bharucha DB, Chen W, Pattathil M; NAC-MD-01 Study Investigators (2014): Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet 383: 1889–1898Google Scholar
  29. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators (2011): Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364: 907–917PubMedCrossRefGoogle Scholar
  30. He B, Zhang F, Li X, Tang C, Lin G, Du J, Jin H (2010): Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ J 74: 1458–1464PubMedCrossRefGoogle Scholar
  31. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWIG) (2009): Vergleichende Nutzenbewertung verschiedener antihypertensiver Wirkstoffgruppen als Therapie der ersten Wahl bei Patienten mit essentieller Hypertonie Version 1.0 vom 15.7.2009Google Scholar
  32. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Jamerson K, Weber MA, Bakris GL, Dahlöf B (2008): Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 359: 2417–2428PubMedCrossRefGoogle Scholar
  33. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E (2014): 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311: 507–520PubMedGoogle Scholar
  34. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR; SHEP Collaborative Research Group (2005): Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95: 29–35PubMedCrossRefGoogle Scholar
  35. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M (2009): Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373: 1275–1281PubMedGoogle Scholar
  36. Larochelle P, Tobe SW, Lacourciere Y (2014): ß-Blockers in hypertension: studies and metaanalyses over the years. Can J Cardiol 30 (5 Suppl): S16–22Google Scholar
  37. Lindholm LH, Carlberg B, Samuelsson O (2005): Should betablockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366: 1545–1553PubMedCrossRefGoogle Scholar
  38. Liu C, Chen J, Gao Y, Deng B, Liu K (2013): Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev; 2: CD00443–4Google Scholar
  39. Montani D, Günther S, Dorfmüller P, Perros F, Girerd B, Garcia G, Jaïs X, Savale L, Artaud-Macari E, Price LC, Humbert M, Simonneau G, Sitbon O (2013): Pulmonary arterial hypertension. Orphanet J Rare Dis 8: 97. [Epub ahead of print]PubMedCentralPubMedCrossRefGoogle Scholar
  40. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A; European Society of Hypertension (2009): Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 27: 2121–2158PubMedGoogle Scholar
  41. Mancia G, Grassi G (2014): Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement. Hypertension 63: 29–36PubMedCrossRefGoogle Scholar
  42. Matsui Y, O’Rourke MF, Hoshide S, Ishikawa J, Shimada K, Kario K (2012): Combined Effect of Angiotensin II Receptor Blocker and Either a Calcium Channel Blocker or Diuretic on Day-by-Day Variability of Home Blood Pressure: The Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study. Hypertension 59: 113–2CrossRefGoogle Scholar
  43. Meisinger C, Heier M, Völzke H, Löwel H, Mitusch R, Hense HW, Lüdemann J (2006): Regional disparities of hypertension prevalence and management within Germany. J Hypertens 24: 293–299PubMedGoogle Scholar
  44. Muntner P, Shimbo D, Tonelli M, Reynolds K, Arnett DK, Oparil S (2011): The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension 57: 160–166PubMedCrossRefGoogle Scholar
  45. National Clinical Guideline Center (2011): Hypertension. The clinical management of primary hypertension in adults. Clinical Guideline 127Google Scholar
  46. National Collaborating Centre for Chronic Conditions (2006): Hypertension (partial update of CG18). London: Royal College of Physicians. Im Internet: http://guidance.nice.org.uk/CG34/guidance/pdf/English
  47. National Institute for Health and Care Excellence (2013): QS28 Qualiti standards for hypertension. Internet: http://publications.nice.org.uk/quality-standard-for-hypertension-qs28
  48. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, Redgrave JN, Bull LM, Welch SJ, Cuthbertson FC, Binney LE, Gutnikov SA, Anslow P, Banning AP, Mant D, Mehta Z; Oxford Vascular Study (2005): Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 366: 1773–1783Google Scholar
  49. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR (2010a): Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 375: 895–905Google Scholar
  50. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, Poulter NR, Sever PS; ASCOT- BPLA and MRC Trial Investigators (2010b): Effects of beta blockers and calciumchannel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 9: 469–480Google Scholar
  51. Roush GC, Holford TR, Guddati AK (2012): Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 59: 1110–1117PubMedCrossRefGoogle Scholar
  52. Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ; SUPER-2 Study Group (2011): Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 140: 1274–1283Google Scholar
  53. Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R (2006): A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 151: 851.e1–5CrossRefGoogle Scholar
  54. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O’Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A (1997): Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350: 757–764PubMedGoogle Scholar
  55. Staessen JA, Gasowski J, Wang Lj G, Thijs L, Den Hond E, Boissel JP, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH (2000): Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355: 865–872PubMedCrossRefGoogle Scholar
  56. Staessen JA, Birkenhäger WH (2005): Evidence that new antihypertensives are superior to older drugs. Lancet 366: 869–871PubMedCrossRefGoogle Scholar
  57. Strange G, Keogh AM, Williams TJ, Wlodarczyk J, McNeil KD, Gabbay E (2008): Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life. Respirology 13: 674–682PubMedCrossRefGoogle Scholar
  58. The ACCORD Study Group (2010): Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med 362: 1575–1585PubMedCentralGoogle Scholar
  59. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2000): Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283: 1967–1975CrossRefGoogle Scholar
  60. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002): Major outcomes in hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288: 2981–2997Google Scholar
  61. The Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW (2010): A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 363: 620–628Google Scholar
  62. The ONTARGET Investigators (2008): Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 358: 1547–1559Google Scholar
  63. The Task Force for the Management of Arterial Hypertension of the ESH and the ESC (2007): 2007 Guidelines for the management of arterial hypertension. J Hypertens 25: 1105–1187Google Scholar
  64. The Task Force for the management of arterial hypertension of the ESH and the ESC (2013): 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 31: 1281–1357Google Scholar
  65. Thijs L, Fagard R, Lijnen P, Staessen JA, Van Hoof R, Amery A (1992): A meta-analysis of outcome trials in elderly hypertensives. J Hypertension 10: 1103–1109CrossRefGoogle Scholar
  66. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, Norgiolini S, Bracco C, Porcellati C (2004): Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects. Hypertension 43: 963–969PubMedCrossRefGoogle Scholar
  67. Weber F, Anlauf M (2014): Treatment resistant hypertension— investigation and conservative management. Dtsch Arztebl Int 2014; 111: __–__.DOI: 10.3238/arztebl.2014.0Google Scholar
  68. Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B (2013): Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 381: 537–545PubMedGoogle Scholar
  69. Wright JT Jr, Fine LJ, Lackland DT, Ogedegbe G, Dennison Himmelfarb CR (2014): Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med 160: 499–503PubMedCrossRefGoogle Scholar
  70. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, Volmink J. (2007): Betablockers for hypertension (Review). Cochrane Database Syst Rev. 2007 Jan 24;(1): CD00200–3Google Scholar
  71. Wiysonge CS, Opie LH (2013): ß-Blockers as initial therapy for hypertension. JAMA 310: 1851–1852PubMedCrossRefGoogle Scholar
  72. Wing LMH, Reid MC, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ; Second Australian National Blood Pressure Study Group (2003): A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348: 583–592PubMedCrossRefGoogle Scholar
  73. Zhu QM, Lesnick JD, Jasper JR, MacLennan SJ, Dillon MP, Eglen RM, Blue DR (1999): Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol 126: 1522–1530PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Manfred Anlauf
    • 1
  • Franz Weber
    • 2
  1. 1.Bremerhaven
  2. 2.St.Walburga KrankenhausMeschede

Personalised recommendations